Deloitte Acquires Fast-Growing Health-Care Data Warehousing and Analytics Firm, Recombinant
NEW YORK, Oct. 29, 2012 /PRNewswire/ -- In a move signaling the growing momentum for using clinical data to transform health care, Deloitte today announced the acquisition of Recombinant Data Corp., a fast-growing provider of data warehousing and clinical intelligence solutions that enable advances in personalized medicine, translational research and health-care performance management.
Based in Newton, Mass., Recombinant's ascendency has been driven by opportunities in the health provider, medical research, life sciences and government health markets as they relate to enterprise data integration, population health analytics, clinical genome data assimilation and performance management for accountable care organizations (ACOs).
Recombinant has enjoyed significant year-over-year growth since it was founded in 2005, defying the economic downturn by emphasizing innovation in helping the health-care industry anticipate a shifting landscape. Recombinant's business will reside within Deloitte Consulting Innovation under the name "Recombinant by Deloitte."
"Joining forces with Recombinant represents a bold move around innovation that will open new horizons for Deloitte in the life sciences and health-care sectors," said Andrew Vaz, principal and chief innovation officer, Deloitte Consulting LLP. "It will extend the Deloitte brand into hybrid business models in which world-class services are combined with advanced intellectual property assets."
According to Peter Emerson, chief executive officer of Recombinant, the combination with Deloitte "multiplies in one event our ability to serve clients while opening new opportunities to deliver our products and services more broadly across the marketplace." Emerson added, "This will allow us to make a greater impact on clients and the direction of health care; Deloitte and Recombinant share the same vision on how the industry is changing, and our combination provides a level of scale that can help reshape the clinical informatics industry."
Jason Girzadas, U.S. managing principal for Deloitte Consulting to the life sciences and health-care industry, added, "This development advances our commitment to provide clients with analytics-based solutions as well as insights that stretch across the spectrum of health sectors. We are excited to have Recombinant as an integral part of our national consulting practice and tightly linked to our life sciences and health-care industry group."
Recombinant's services and products help enable the data management that underpin the formation of value-based payment models that link different health players around patient care. Recombinant also helps academic medical centers, federal agencies and life sciences companies conduct translational research and analyze phenomic, genomic and bio banking data in pursing personalized and evidence-based medicine. These solutions can help clients unlock the underlying power of digital data.
"This addition puts Deloitte in a stronger position to help health organizations solve their most complex problems as they adjust to new approaches to care delivery," said Vaz, who noted that pressure continues to mount for fundamental changes in health care.
About Deloitte's Life Sciences and Health-Care practice
Deloitte's life sciences and health-care practice is a market leader bringing fresh insight to clients and industry stakeholders. Deloitte offers a distinctive menu of professional services delivered in an integrated approach that address all segments of the health plan, health provider and life sciences industries across commercial, federal and state sectors. For more information, visit www.deloitte.com/view/en_US/us/Industries/index.htm.
About Recombinant by Deloitte
Recombinant offers health-care providers and academic medical centers proven, leading-edge data warehousing and clinical intelligence solutions to deliver higher quality outcomes, accelerate personalized medicine, and lower costs. Our team of industry veterans is focused on improving the flow of reliable data to power clinical and research applications in a secure, compliant environment.
As used in this document, "Deloitte" means Deloitte Consulting LLP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.